This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

EV0503

Insulin-like growth factor-1 and recovery in anorexia nervosa: evidence from population-based and clinical cohorts

IGF-1 AND RECOVERY IN ANOREXIA NERVOSA: EVIDENCE FROM POPULATION-BASED AND CLINICAL COHORTS

IGF-1 levels decrease progressively across illness stages, increase with weight restoration and treatment, and are independently associated with the recovery of menstrual function.

The aim was to examine growth hormone (GH) resistance and low insulin-like growth factor-1 (IGF-1) levels across illness stages in anorexia nervosa (AN), and their associations with metabolic and reproductive parameters. A cross-sectional, population-based analysis was conducted within the UK Biobank, comparing 129 individuals with current AN (C-AN), 2,380 individuals with weight-restored AN (WR-AN), and 2,380 healthy controls (HC) matched for age and body mass index (BMI). An independent clinical cohort of 189 adult women was also assessed at baseline and at 12 months; group differences were examined using adjusted ANCOVA, and longitudinal changes using mixed-effects models. IGF-1 levels were 19.80±5.07 in the C-AN group, 21.70±5.69 in the WR-AN group, and 22.21±5.77 nmol/L in the HC group, with a significant difference between groups (F=11.10, p<0.001; post-hoc Tukey a<b<c). BMI values were 17.48±0.98, 22.97±3.90, and 23.04±3.47 kg/m2, respectively (F=144.30, p<0.001), whereas there was no difference in age (F=1.14, not significant). In the clinical cohort, IGF-1 levels increased significantly over 12 months (p=0.003) and were positively associated with insulin, glucose, and FT3, and negatively associated with GH. Higher IGF-1 levels were independently associated with the recovery of menstrual function (p<0.001). In conclusion, IGF-1 is associated with metabolic status and reactivation of the reproductive axis in AN and may be a clinically informative biomarker of illness severity and treatment response.

All WCP 2026 summaries